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Renal transplantation In baboons under FK 
506 
Satoru Todo, MD, Anthony Demetris, MD, Yuji Ueda, MD, Oscar Imventarza, MD, 
Evan Cadoff, MD, Andriana Zeevi, MD, and Thomas E. Starzl, MD, PhD, Pittsburgh, Pa. 
FK 506 was tested in unrelated baboons submitted to renal transplantation and 
bilateral native nephrectomy. Untreated baboons died after 9.2 ± 4.0 SD days. When 
FK 506 was given orally for 90 days, survival with the optimum dose was 74.6 ± 28.9 
days; this allowed maximum credit for each individual animal of 90 days. A 3-day 
course of intramuscular FK 506 started on postoperative day 4 allowed 1- to 2-month 
survival. Delayed rejection in these baboons as well as in those treated daily for 90 days 
with FK could sometimes be reversed temporarily with a second 3-day course. The 
doses required for a good therapeutic effect were 10 times greater in baboons than in 
dogs, a finding that may reflect a species difference of lymphocyte sensitivity to this 
drug. FK appeared to be relatively nontoxic in subhuman primates, and it remains a 
promising drug for clinical trial. (SURGERY 1989;106:444-51.) 
From the DejJartments of Surgery and Pathology, University Health Center of Pittsburgh, 
University of Pittsburgh, and the Veterans Administration Medical Center, Pittsburgh, Pa. 
ALTHOUGH THE REMARKABLE immunosuppressive po-
tency of FK 506 has been established in rodents and 
dogs,1-6 prohibitive toxicity has been described by one 
group of investigators in dogs7 and in baboons.s,9 We 
have observed moderate toxicity in dogs4, 6 but few side 
effects in rats lO and in baboons or cynomolgus mon-
keys.6 However, the prevention of renal homograft re-
jection in our subhuman primate studies was incomplete 
and unreliable,6 suggesting the possibility of underdos-
age. Consequently the safety and efficacy studies re-
ported here were undertaken in baboons. 
METHODS 
Animals and operative procedures. Half of the 
out bred unrelated baboons (Papio anubis) were bred 
and raised at the Southwestern Foundation for Bio-
medical Research, San Antonio, Texas. The other half 
were purchased from the Charles River Primate Cor-
poration, Port Washington, N.Y. All of the recipients, 
as well as the weight-matched donors, were females 
weighing 8 to 14 kg. Blood types were determined and 
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all donor-recipient combinations were ABO identical 
(88%) or compatible (12%). Donor-recipient cytotoxic 
antibody crossmatches were negative in all of the 
experiments. 11 One-way mixed lymphocyte reactions 
were determined. 12 The results were not used for donor 
selection, but these will be summarized in the present 
report and described separately in detail. 
After an overnight fast, the animals were anesthesized 
with 10 mg/kg of intramuscular (1M) ketamine, intu-
bated, and placed on a ventilator. Anesthesia was main-
tained with a mixture of oxygen, nitrous oxide, and 
halothane. Renal transplantation was performed intra-
abdominally, with end-to-side anastomoses of a renal 
artery Carrell patch to the abdominal aorta and of the 
renal vein to the inferior vena cava. Ureteroneocys-
tostomy was performed, and the native kidneys of the 
recipients were removed. One gram of cephalosporin 
was given during the operation and daily for 3 days. 
Animals were fed beginning the next morning. A total 
of 30 renal transplantations were performed to obtain 23 
complete experiments. Within 5 days the other seven 
animals died of technical complications such as graft 
vessel thrombosis or bleeding. These seven animals were 
not included in the analyses. 
Drug administration. FK 506 for oral or 1M 
administration was supplied as a powder by the Fuji-
sawa Pharmaceutical Co., Ltd., Osaka, Japan. The FK 
for 1M use was suspended in normal saline solution, 4 
mg/ml. Oral FK for morning administration was sus-
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Table I. Experimental groups and treatment regimens of FK 506 for baboons after renal transplantation 
fM FK* OmIFK* fA1 FK 
(mg/kg/day) , 
on days 
4,5,6 
fMFK 
(mg/kg/day) , 
when creatinine 
for 3 days elevated 
>3 mg/dl 
(mg/kg/day) , (mg/kg/ day) , 
on days after day 4 
Group n 1,2,3 until day 90 
Chronic treatment 
1 4 
2 2 0.5 2.0 
3 4 1.0, DD 6.0, DD 
4 5 2.0, DD 12.0, DD 2.0* 
2.0* 5 5 2.0, DD 18.0, DD 
Brief treatment 
6 2 
7 
LCJ{cnd: DD, Divided dose. 
2.0 
10.0 
2.0 
10.0 
*\lVith animals who lived for more than 90 days with discontinuance of oral FK treatment. 
pended in 20 ml of normal saline solution and given 
through a gastric tube after the animals were anesthe-
sized with 5 mg/kg of ketamine. For evening adminis-
tration, FK was mixed with fruit paste or dispersed onto 
pieces of fruit. Complete acceptance of the FK was 
carefully observed (until animals ate them all). 
Experimental groups. The 23 recipients (Table I) 
included 4 untreated control animals (group 1); three 
animals that were treated for 3 days only with intra-
muscular FK beginning on day 4 (brief treatment, 
groups 6 and 7), and 16 animals treated for a maximum 
of 90 days (long-term treatment, groups 2 to 5). 
Most of the animals treated for the longer period were 
given FK in divided doses (Table I). Animals in which 
late rejection occurred when therapy was discontinued 
in both the long-term (groups 4 and 5) and brief treat-
ment groups (groups 6 and 7) were given 3-day rescue 
courses of 1M FK. 
Biochemical studies. Blood samples were collected 
routinely on the mornings of operations, before FK 
administration on postoperative days 4, 7, 10, and 14 
and once a week thereafter. More sampling was added 
as needed, while the animals were under 1M treatment 
or during rejection. Creatinine, blood urea nitrogen, as-
partate aminotransferase, alanine aminotransferase, 
total bilirubin, and blood glucose levels were deter-
mined. FK plasma levels were measured by enzyme 
immunoassay with a monoclonal antibody to FK.13 
Pathologic studies. Animals that became deeply le-
thargic were killed for humane reasons with 25 mg/kg 
of pentobarbital and 0.2 ml/kg of Beuthanasia solution. 
Animals that lived for more than 90 days with daily oral 
FK treatment were anesthetized and biopsy specimens 
were taken from the kidney graft, liver, and pancreas. 
All of the samples were fixed with neutral buffered for-
malin. Histopathologic analyses were performed blindly 
without knowledge of postoperative course, type or dos-
age of immunosuppressive therapy, or length of sur-
vival. Histologic severity of acute cellular graft rejection 
was scored according to subjective scales, from none to 
severe. 
Statistics. The values were described as the mean 
plus or minus standard deviation. When survival was 
computed, the maximum credit given to any animal was 
90 days. The Mann-Whitney V test, the Student t test, 
and the X2 test were used for statistical analyses. The 
difference in group means was considered significant if 
the probability was less than 0.05. 
RESULTS 
General clinical behavior 
All of the animals became inactive and depressed for 
the first 3 to 5 days after their operations, but those 
treated with effective doses of FK recovered soon after-
ward. Severe diarrhea or vomiting was not seen in the 
treated animals. There was variable loss of body weight 
for the first several weeks after the operations. This did 
not correlate with the FK dose, and ultimately weight 
gain occurred toward or beyond the preoperative level 
in eight of the ten baboons that survived for more than 
1 month. 
Untreated controls 
Survival was for 5 to 14 days (Fig. 1, Table II), for 
a mean of 9.2 ± 4 (SD) days. Renal failure developed 
rapidly in the baboons (Fig. 2, Table II); this was shown 
by the histopathologic studies (Table II) to have been 
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Table II. Survival, severity of graft rejection, and cause of death of animals with no treatment and chronic 
treatment with FK (observations limited to first 90 days) 
["atest graft function * 
Animal Survival Histologic severityJ Creatinine BUN Cause of 
Groups No. (days) MLRt of graft rejection (mg/dl) (mg/dl) animal death 
87 11 None 3 24.3 300 Rejection 
90 7 Low 2 to 3 16.5 154 Rejection 
106 5 Middle 1 to 2 14.2 98 Rejection 
112 14 NT 3 13.0 100 Rejection 
2 95 14 NT 2 19.3 273 Rejection 
97 18 NT 3 17.5 264 Rejection 
3 104 23 NT 3 23.3 84 Rejection 
107 76 None 2to3 8.4 229 Rejection 
100 12 NT 1 5.5 114 Renal vein thrombosis (?) 
110 7 Low 14.4 97 Rejection 
4 10 >90 High 2 0.8 68 
21 30 High 1 to 2 11.1 448 Rejection 
23 >90 High 0 0.7 22 
28 54 Low 2 15.8 263 Rejection 
6 >90 Middle 1.0 21 
5 29 23 High 2 to 3 22.1 289 Rejection 
9 >90 High 1 to 2 1.5 71 
24 84 High 0 3.9 225 Unknown (anemia?) 
5 86 High 0 24.1 39 Pyelonephri tis 
26 >90 High 1.1 22 
*Graft function at the latest measurement or at the 90th postoperative day. 
tMI.R (mixed lymphocyte reaction): none (no re,p<)Qse), low «5,000 cpm), middle «10,000 cpm), high (>10,000 cpm), NT (not tesled) 
tHistologic severity; 0 (none), 1 (mild), 2 (moderate), and 3 (severe) al the time of sacrifice or biopsy at the 90th day. 
Table III. All postoperative AST, ALT, total bilirubin, blood glucose, and FK levels in baboons of groups 1 to 5 
(mean ± SD) 
Dose of Serum 
oral FK AST 
Groups' (mg/kg/day) n (U/L) 
0 4 49.5 ± 49.5 
2 2 2 38.7 ± 19.7 
3 6 4 45.0 ± 20.3 
4 12 5 51.0 ± 28.8 
5 18 5 49.4 ± 30.9 
/,egenl/: AST, Aspartate aminotransferase; AI,T, alanine aminotransferase. 
caused by rejection. Liver function tests and fasting 
blood glucose values are shown in Table III. 
Long-term FK treatment 
Survival. Consistent prolongation of survival was 
achieved only with the high doses given to the animals 
of groups 4 and 5 (Fig. 1, Table II). Nine of the 10 an-
imals in these two groups lived for at least 1 month, 
seven lived for at least 84 days, and five completed the 
full 90 days of treatment. There was no correlation be-
Serum 
Serum total Blood Plasma 
ALT bilirubin glucose FK 
(U/L) (mg/dl) (mg/dl) (ng/ml) 
12.0 ± 13.7 0.7 ± 0.4 103 ± 4 
37.4 ± 40.5 0.5 ± 0.5 87 ± 78 1.26 ± 1.20 
25.4 ± 17.6 0.4 ± 0.4 104 ± 20 4.27 ± 2.87 
29.7 ± 28.6 0.2 ± 0.2 86 ± 76 3.26 ± 1.85 
36.4 ± 64.6 0.4 ± 0.8 102 ± 43 5.24 ± 5.00 
tween mixed lymphocyte reactions and the outcome 
(Table II). A survival effect was discernible in the low-
er-dosage groups 2 and 3, but this was minor (Fig. 1, 
Table II). In group 4, survival was 70.8 ± 27.6 (SD) 
days, giving a maximum credit to any animal of 90 days. 
Group 5 animals survived for 74.6 ± 28.9 (SD) days. 
Biochemical studies. The dose/ effect relationshi p was 
even more evident in the tests of renal function (Fig. 2, 
Table II). Uremia was a universal funding with the 
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Fig. 1. Survival of baboons after renal transplantation under FK 506. Doses shown are oral FK given from the 
fourth postoperative day until the 90th day. Intramuscular doses were also given on days 1 to 3 (see Table I). 
lower doses, but it was not found in the animals of 
groups 4 and 5. 
Liver function and blood glucose levels were not sig-
nificantly different than in the untreated control animals 
(Table III). 
FK plasma levels. The mean trough plasma levels 
from all postoperative determinations in the chronically 
treated baboons are given in Table III. Serial measure-
ments from these animals are shown in Fig. 3. 
Pathologic studies oj the grajts. Histopathologic signs 
of moderate or severe rejection were found in all of the 
grafts in the controls and in low-dose group 2 (Table II). 
The signs of rejection were slightly less developed in 
animals of group 3. Half of the 10 grafts in groups 4 and 
5 had moderate rejection histopathologically, but these 
findings did not correlate well with renal function 
(Table II). The two grafts from animals that died while 
still under treatment after 84 and 86 days did not con-
tain evidence of rejection. One of these animals died of 
pyelonephritis; the cause of death could not be deter-
mined in the other. 
In four of the five animals that survived for 3 
months and whose therapy was stopped rejection sub-
sequently developed (Fig. 4). In two animals, the rejec-
tion was reversed with a 3-day course of 1M FK (Fig. 
4). Eventually, all four of these baboons died after a to-
tal survival of 116 to 233 days. At autopsy, three of the 
four grafts showed chronic rejection, a finding (mild in-
terstitial fibrosis) that had been present in only one of 
them at day 90; the fourth graft infarcted between days 
90 and 116 and could not be adequately evaluated his-
topathologically. One baboon is still alive more than 190 
days after transplantation and 100 days after discon-
tinuance of therapy. The 90-day biopsy specimen from 
this animal showed no rejection. 
Pathologic studies oj the extrarenal organs. The con-
trol animals and the animals of low-dose groups 2 and 
3 did not have arteritis in the heart, liver, pancreas, 
lungs, stomach, intestine, and spleen. The five animals 
in the combined groups 4 and 5 that died before 90 days 
while undergoing higher-dose daily FK treatment orally 
did not have arteritis, with the exceptions of a single 
vessel with fibrinoid change in the appendix of animal 
24 and a single similar vessel in the stomach of animal 
29. The biopsy specimens of the liver and pancreas ob-
tained from the other five animals that were alive at 90 
days were free of arteritis. 
Four of these five baboons died later, and autopsies 
were performed 26 to 143 days after daily FK treatment 
was stopped at 90 days (Fig. 4). One of these four ani-
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Fig. 2. Changes in serum creatinine. Doses of FK are as 
shown in Fig. 1. 
mals had focal necrotizing arteritis in the gastric sub-
mucosa (animal 6) but nowhere else. This baboon, which 
died of renal failure, had been given a 3-day course of 
1M FK 506 on postoperative days 105, 106, and 107 and 
was given another single injection on the day before 
death (Fig. 4). Animal 9 had mild degenerative change 
in a single intramyocardial artery. Rejection was the 
cause of death in spite of two "rescue" courses of 1M FK 
506, of which the last was 34 days before death (Fig. 4). 
Vacuolization of the parenchymal cells was seen 
occasionally but was not associated with dose. One ba-
boon (No. 10) that had malaria died of intrahepatic bile 
duct necrosis 138 days after transplantation and 48 days 
after cessation of daily FK (Fig. 4). Another animal 
(No. 21) had severe acute cholangitis 30 days after 
transplantation. 
An animal (No. 26) that died after 116 days of renal 
failure due to rejection (Fig. 4) had a small area of my-
ocardial necrosis; this was the animal whose kidney was 
infarcted 26 days after cessation of daily FK treatment. 
Subendocardial fibrosis and focal calcification were 
present in an animal (No. 28) that died of rejection 54 
days after transplantation. 
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Fig. 3. Plasma trough levels of FK 506 after renal trans-
plantation. Troughs in group 2 are at 24 hours, and in groups 
3 to 5 troughs are at 12 hours. 
Brief FK treatment 
The three animals of groups 6 and 7, who were given 
3 days of 1M FK on days 4,5, and 6, retained good graft 
function for 1 to 2 months (Fig. 5). When renal func-
tion deteriorated, a further 3-day course reversed the 
rejection. However, a second bout of renal failure that 
ensued after another 20 days to 2 months was refractory 
to treatment (Fig. 5). 
Autopsies of these three animals after 82, 106, and 
122 days showed acute and chronic rejection of the 
grafts. The animal (No. 50) that survived 122 days with 
three 3-day 1M treatment courses had extensive necro-
tizing arteritis in the small intestine, duodenum, and 
heart. Animal No. 25, treated in a similar way (Fig. 5), 
had parasitosis and necrotizing granulomas of the intes-
tine. Animal 51 had hemorrhagic gastritis and closed-
loop intestinal obstruction; there was mild fibrinoid 
change in one intramyocardial artery in this animal. 
DISCUSSION 
The results from this study permit cautious optimism 
about impending clinical trials with FK 506. Particu-
larly encouraging was the absence of major toxicity, 
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Fig. 4. Survival and graft function of five baboons who lived 
for 90 days and had daily FK stopped. Beyond 90 days, each 
arrow represents an intramuscular administration of 2 mg/kg . 
FK 506. 
even when daily doses used over a 3-month period were 
10 times higher than those that can cause lethal emaci-
ation in dogs.4, 6, 7 Although there were a few examples 
of arteritis in the liver, heart, and stomach, these usu-
ally were in animals that were undergoing acute and 
chronic rejection long after daily FK treatment had been 
stopped. Formal toxicology studies done by the Hun-
tington Laboratories, Cambridge, England, have shown 
no such lesions with doses up to 36 mg/kg for 13 weeks 
(Nishiyama M, personal communication). Reports that 
FK 506 caused diabetes, lassitude, and other serious or 
lethal side effects in baboons8, 9 could not be confirmed. 
The unexpectedly high doses required for a thera-
peutic effect prompted an internal examination of 
several factors that might have been responsible. The 
quality of the drug was checked by scientists at the 
Fujisawa Corporation. 14 Degradation during storage 
was ruled out with stability tests, and the kinetics of 
absorption in baboons and dogs were studied and 
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Fig. 5_ Survival and serum creatinine of baboons after renal 
transplantation and 3-day intramuscular courses of FK 506. 
No other treatment was given. Each arrow represents one 
dose. 
found to be similar (Venkataramanan R, personal 
communications). Eventually, Zeevi et aL15 showed 
with mixed lymphocyte reactions testing that baboon 
lymphocytes are more resistant to FK than the lym-
phocytes of dogs. It is important to note that human 
lymphocyte sensitivity is closer to that of dogs than to 
that of baboons.16 
The safeguards for the first clinical trials of FK 506 
are unusually complete as exemplified by the availabil-
ity of a highly specific system to assay plasma and tissue 
levels of this drug.13 However, failure of the plasma 
trough levels to sensitively reflect large variations in 
dosage in the baboons was disappointing. It will be es-
sential to carry out careful pharmacokinetic studies in 
the phase I clinical trials to see if the same pertains in 
human recipients. 
In previous canine experiments with kidney and liver 
transplantation, an unusually prolonged biologic action 
of short courses of FK was noted. 6 The same thing was 
noted in the baboon kidney recipients herein reported 
who were given a 3-day course of 1M FK 506 on days 
4, 5, and 6 and after transplantation. The grafts func-
tioned for 1 to 2 months before there were signs of re-
jection, and even then the rejections could be reversed 
with a second 3-day course. However, none of the an-
imals was tolerant. Even after 3 months of daily treat-
450 Todo et ai. 
ment with FK (groups 4 and 5), discontinuance of ther-
apy was usually followed by rejection. 
These studies in baboons were conducted with a 
single agent. As with previously used immunosuppres-
sive drugs, however, FK will probably be used clinically 
as part of a pharmacologic cocktail. The synergism of 
FK with other agents, particularly with cyclosporine, 
has been unequivocally shown both in vitro16-18 and in 
vivo.3, 4, 6 The possibility of exploiting this synergism in 
a clinical setting seems good_ 
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DISCUSSION 
Dr. Ronald M. Ferguson (Columbus, Ohio). I disagree 
with your last conclusion. I think it probably is not ready for 
clinical trials yet, and I have a number of questions about that. 
You have provided almost no evidence to suggest that FK 506 
is any better than what we already have; nor have you provided 
any theoretical basis for slipping FK 506 into some rational 
theoretically based immunosuppressive protocol. Its mecha-
nism of action is much like that of cyclosporine. How does this 
compare with our current immunosuppressive protocols? And 
why is it better? How do you see this if it were to go into clin-
ical trials-being used as a single agent, or in combination 
with other agents? Is there any other theoretical basis for the 
immunosuppressive protocol to be used clinically that would 
include FK 506? 
Dr. Todo. Our suggestion that a clinical trial would be 
proper is based on exhaustive animal studies carried out in 
rats, dogs, and subhhuman primates during the last 2% years. 
These were summarized at the meeting last year of SUS and 
at other major meetings. By itself, FK 506 is at least as effec-
tive as cyclosporine in all three species, and probably more so. 
lt has been demonstrated to be synergistic with cyclosporine 
and also with azathioprine. It is hoped, but not proved, that 
FK will be less nephrotoxic than cyclosporine. The work sup-
porting these statements is extensively cited in the bibliogra-
phy of our paper and in the bibliography of our SUS paper 
last year. The most likely use of FK will be with low doses of 
cyclosporine and steroids. 
Dr. Francis T. Thomas (Greenville, N.C.). Dr. Ferguson 
has asked two key questions. We presented our results with 
FK testing at the Surgical Forum and at the Xeno 25 meeting 
last fall. In agreement with Dr. Todo, we have found the drug 
to be a unique immunosuppressive agent with quite a bit of 
potency. We used a difficult xenograft model that is not pro-
longed by any of the currently available suppressive agents. 
Even in combination with total lymphoid irradiation and cy-
closporine as reported by others, we could not get significant 
prolongation in this model. It is a very difficult model. FK 
alone and in synergism with rat ATG was the only suppres-
sive agent that seemed to work in this model. As for the tox-
icity, however, we do find significant toxicity of the drug in 
primates and in lower animals also. In our experience with 
more than 300 primates given kidney grafts, the peri operative 
mortality is essentially zero. I wonder if seven baboons of the 
30 renal recipients in your study that died during the early 
postoperative period did not die of drug toxicity. 
The second point, where I think we are probably at stron-
gest variance with your findings, is that, in our experience, the 
use of cyclosporine in combination with FK produced a pro-
hibitive mortality. This approached 60% to 80%, regardless of 
the combination of the drugs given, and also had a poor im-
munosuppressive effect. FK dose ranged from 0.5 mg/kg/day 
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to 12 mg/kg/day. We could not get immunosuppressive 
potency without significant toxicity with the cyclosporine in 
your clinical trials. 
Dr. Todo. The seven aminals that died within 5 days after 
renal transplant included nontreated controls as well as treated 
animals. Thrombosis of the renal artery and intra-abdominal 
bleeding were the main causes of animal death. FK 506 with 
cyclosporine in rodents and dogs at subtherapeutic as well as 
therapeutic doses showed significant prolongation of graft and 
animal survival and was safe. This was the principal message 
of our SUS paper last year. 
Dr. K. Hockerstedt (Helsinki, Finland). Although you 
FK 506 and renal transplant in baboons 451 
have shown that FK 506 suppresses acute rejection without 
toxicity in your model, I would like to ask if you have tried to 
evaluate why this drug is so efficient in suppressing acute re-
jection, and if you have measured the T-cell levels in blood? 
Dr. Todo (closing). The mechanism of the suppression of 
acute rejection by brief intramuscular FK treatment is now 
under study. With heterotopic heart and orthotopic liver 
transplantation in rats, we did not see any difference in the 
T-cell sub population in the blood before and after this treat-
ment (unpublished data), although massive infiltration of 
lymphocytes in these organs subsided progressively in some 
animals. 
